Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 7/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914916 | 0.98 | PAOX (0.52) | PAOXQPCTKDM1AHRH4MAOB | |
| SCHEMBL16372492 | 0.93 | QPCT (0.50) | QPCTHRH4HRH2KMT2AALDH1A1 | |
| SCHEMBL12913670 | 0.86 | ALDH1A1 (0.62) | PAOXKDM1AHRH4MAOBHRH2 | |
| SCHEMBL14860830 | 0.85 | KMT2A (0.53) | QPCTHRH4HRH2KMT2AALDH1A1 | |
| SCHEMBL1276262 | 0.84 | ALDH1A1 (0.56) | QPCTHRH4HRH2KMT2AALDH1A1 | |
| SCHEMBL12914925 | 0.84 | ALDH1A1 (0.59) | PAOXKDM1AHRH4MAOBHRH2 | |
| SCHEMBL20052940 | 0.84 | QPCT (0.45) | PAOXQPCTHRH4HRH2KMT2A | |
| SCHEMBL11593207 | 0.81 | EPHX1 (0.61) | QPCTHRH4HRH2KMT2AMEN1 | |
| SCHEMBL11595839 | 0.81 | EPHX1 (0.61) | QPCTHRH4HRH2KMT2AMEN1 | |
| SCHEMBL11595115 | 0.81 | EPHX1 (0.61) | QPCTHRH4HRH2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708255-B2 | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | Casero, Robert A. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708255-B2 | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | Casero, Robert A. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20120322877-A1 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-12-20 | — | — | US | disclosed |
| US-20120322877-A1 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-12-20 | — | — | US | disclosed |
| WO-2011022489-A2 | (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322877-A1 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | KDM4A, KDM1A, EHMT1 | PAOX 2689/4885QPCT 2681/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.